CAPA Statement on House Judiciary Committee Votes to Address Big Pharma’s Patent Abuse
Congress Must Act to Prevent Anti-Competitive Tactics Used by Many Major Pharmaceutical Companies to Keep Low-Cost Alternatives Out of the Marketplace
WASHINGTON D.C. – The Coalition Against Patent Abuse released the following statement after the House Judiciary Committee passed three bills relating to patent reform and drug pricing, including H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act, and H.R. 2883, the Stop Stalling Access to Affordable Medications Act. Together, these bills aim to reduce anticompetitive product-hopping and curtail the creation of large patent thickets, among other anti-competitive tactics, used by Big Pharma to prevent or indefinitely delay competition from entering the marketplace.
“CAPA applauds lawmakers on both sides of the aisle for passing these three bills out of Committee as an important step towards stopping anti-competitive abuses of regulatory process,” stated CAPA Executive Director Matthew Lane. “Congress must continue to make progress on ensuring more competition in the marketplace so millions of American patients can access more affordable generic alternative medications and treatments. It is also imperative that Congress and the Administration keep working to strengthen the inter partes review process, which has proven to be an effective tool used by the U.S. Patent and Trademark Office to identify anti-competitive patent practices and invalidate low-quality patents.”
To watch a video of the markup, click here.